• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

The recommendations listed in this clinical practice guideline are, whenever possible,
evidence-based. An initial extensive evidence review, which included literature derived from …

Shared decision making for advanced heart failure has become both more challenging and
more crucial as duration of disease and treatment options have increased. High-quality …

A Critical Appraisal of Implantable Cardioverter-Defibrillator Therapy for the Prevention of
Sudden Cardiac Death Roderick Tung, Peter Zimetbaum, Mark E. Josephson The …

Significant mortality benefits have been documented in recipients of implantable
cardioverter defibrillators (ICDs); however, the psychosocial distress created by the …

Background The benefits of implantable cardioverter-defibrillators (ICDs) have been well
demonstrated in many clinical trials, and ICD shocks for ventricular tachyarrhythmias save …

Cardiac electrical storm (ES) is characterised by three or more discrete episodes of
ventricular arrhythmia within 24 hours, or incessant ventricular arrhythmia for more than 12 …

Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is a genetic form of
cardiomyopathy (CM) usually transmitted with an autosomal dominant pattern. It primary …

Despite the indisputable mortality advantages of implantable cardioverter defibrillators
(ICDs), no consensus exists regarding their impact on quality of life (QoL). This systematic …

The implantable cardioverter-defibrillator (ICD) has rev-olutionized the care of patients at
risk for life-threatening arrhythmias. Large-scale clinical trials established mortality benefits …